title: Liver preservation with SCOT 15 solution decreases posttransplantation cholestasis compared with University of Wisconsin solution: a retrospective study.
abstract: BACKGROUND
  SCOT 15 is a new solution to preserve abdominal organs for transplantation. Its principal characteristic is the use of polyethylene glycol. Herein We report our experience using SCOT 15 compared with the reference University of Wisconsin (UW) solution for hepatic transplantation.
  
  
  METHODS
  We compared 2 groups: SCOT 15 (n = 33; 2009-2010) versus UW (n = 34; 2008-2010), which were paired for cold and warm ischemic times, donor ages, and graft weights. Endpoints were biologic tests in the first 2 months after the operation. A linear mixed model was used to evaluate longitudinal changes and influences of each solution.
  
  
  RESULTS
  No primary failure was observed. At postoperative day 0, transaminase values were higher in the SCOT 15 than in the UW group: aspartate transaminase: 2,435 ± 399 vs 589 ± 83 IU/L (P < .01); alanine transaminase: ALT: 1,207 ± 191 vs 484 ± 64 IU/L (P < .05), then returned to low levels in both groups. From day 0 to 8, coagulation factors reached normal values; there was no difference between the 2 groups. Total bilirubin decreased similarly in the 2 groups. However, from the second postoperative week (W1) to W8, the SCOT 15 group showed a slow decrease in the mean values of gamma-glutamyltranspeptidase (gGT) from 233 ± 125 to 130 ± 161 IU/L, which were significantly lower than those in the UW group, where the gGT remained around 300 IU/L (P < .01). The End-Stage Liver Disease, Child-Pugh, or United Network for Organ Sharing scores, primary liver diseases, hepatitic C virus status, arterial or biliary complications, and male/female ratio, which was different in the 2 groups, did not statistically influence these results.
  
  
  CONCLUSIONS
  The main effect of cold storage of human liver using SCOT 15 compared with UW solution was to decrease cholestasis following transplantation.
authors.affiliation: Service de Chirurgie Digestive et Hépato-Bilio-Pancréatique-Transplantation Hépatique, Groupe Hospitalier Pitié-Salpêtrière, Paris, France. eric.savier@psl.aphp.fr
authors.forename: E
authors.initials: E
authors.lastname: Savier
authors.forename: B
authors.initials: B
authors.lastname: Granger
authors.forename: F
authors.initials: F
authors.lastname: Charlotte
authors.forename: N
authors.initials: N
authors.lastname: Cormillot
authors.forename: J M
authors.initials: JM
authors.lastname: Siksik
authors.forename: J C
authors.initials: JC
authors.lastname: Vaillant
authors.forename: L
authors.initials: L
authors.lastname: Hannoun
mesh_terms: D000241:Adenosine / Q000494:pharmacology; D000493:Allopurinol / Q000494:pharmacology; D002779:Cholestasis / Q000517:prevention & control*; D005260:Female; D005978:Glutathione / Q000494:pharmacology; D006085:Graft Survival; D006801:Humans; D007328:Insulin / Q000494:pharmacology; D008099:Liver / Q000473:pathology*; D017093:Liver Failure / Q000628:therapy; D016031:Liver Transplantation / Q000009:adverse effects / Q000379:methods*; D008297:Male; D008875:Middle Aged; D009926:Organ Preservation / Q000295:instrumentation* / Q000379:methods*; D019188:Organ Preservation Solutions / Q000494:pharmacology*; D011092:Polyethylene Glycols / Q000737:chemistry; D011183:Postoperative Complications / Q000517:prevention & control; D011887:Raffinose / Q000494:pharmacology; D012189:Retrospective Studies; D013997:Time Factors; D016896:Treatment Outcome
chemical_list: D007328:Insulin; D019188:Organ Preservation Solutions; C055206:University of Wisconsin-lactobionate solution; D011092:Polyethylene Glycols; D000493:Allopurinol; D005978:Glutathione; D000241:Adenosine; D011887:Raffinose